44,867 Shares in Becton, Dickinson and Company $BDX Purchased by Ascent Wealth Partners LLC

Key Points

• Ascent Wealth Partners purchased a new 44,867-share stake in Becton, Dickinson and Company during the third quarter, valued at approximately $8.03 million. Institutional investors collectively own 86.97% of BDX.
• BD reported quarterly earnings of $3.23 per share, exceeding estimates of $3.14, while revenue reached $4.98 billion and rose 5.4% year over year. The company maintained fiscal 2026 guidance of $12.62–$12.72 in adjusted EPS.
• The company pays a quarterly dividend of $1.05 per share, equivalent to an annualized $4.20 and a 2.1% yield. Analysts’ consensus rating is Moderate Buy, with an average price target of $185.07.

Ascent Wealth Partners LLC bought a new stake in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 44,867 shares of the medical instruments supplier's stock, valued at approximately $8,031,000.

Other large investors have also made changes to their positions in the company. BlackRock Inc. bought a new stake in Becton, Dickinson and Company in the second quarter worth approximately $3,721,533,000. State Street Corp increased its position in Becton, Dickinson and Company by 8.5% during the second quarter. State Street Corp now owns 15,000,064 shares of the medical instruments supplier's stock worth $2,269,960,000 after buying an additional 1,177,256 shares during the last quarter. First Eagle Investment Management LLC increased its position in Becton, Dickinson and Company by 15.8% during the second quarter. First Eagle Investment Management LLC now owns 13,815,335 shares of the medical instruments supplier's stock worth $2,090,675,000 after buying an additional 1,887,224 shares during the last quarter. Bank of America Corp DE bought a new position in Becton, Dickinson and Company during the second quarter valued at about $474,993,000. Finally, Legal & General Group Plc raised its holdings in Becton, Dickinson and Company by 1.5% during the second quarter. Legal & General Group Plc now owns 2,101,695 shares of the medical instruments supplier's stock valued at $318,050,000 after buying an additional 30,766 shares in the last quarter. Institutional investors own 86.97% of the company's stock.

Becton, Dickinson and Company Price Performance

Shares of NYSE BDX opened at $198.96 on Friday. The stock has a market capitalization of $54.82 billion, a price-to-earnings ratio of 59.93, a PEG ratio of 13.41 and a beta of 0.21. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.87 and a quick ratio of 0.51. Becton, Dickinson and Company has a fifty-two week low of $127.59 and a fifty-two week high of $200.47. The business has a 50-day moving average of $185.41 and a 200-day moving average of $165.10.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last released its earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share for the quarter, beating the consensus estimate of $3.14 by $0.09. The business had revenue of $4.98 billion during the quarter, compared to analysts' expectations of $4.89 billion. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The firm's revenue was up 5.4% on a year-over-year basis. During the same period last year, the business earned $3.68 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. As a group, sell-side analysts predict that Becton, Dickinson and Company will post 12.67 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Wednesday, September 30th. Stockholders of record on Wednesday, September 9th were paid a dividend of $1.05 per share. The ex-dividend date was Wednesday, September 9th. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.1%. Becton, Dickinson and Company's dividend payout ratio (DPR) is 126.51%.

Insiders Place Their Bets

In other news, EVP Michael Feld sold 165 shares of the business's stock in a transaction that occurred on Wednesday, August 26th. The shares were sold at an average price of $188.49, for a total value of $31,100.85. Following the completion of the transaction, the executive vice president directly owned 19,720 shares in the company, valued at approximately $3,717,022.80. The trade was a 0.83% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Roland Goette sold 2,438 shares of the company's stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $180.84, for a total value of $440,887.92. Following the sale, the executive vice president owned 14,856 shares of the company's stock, valued at approximately $2,686,559.04. This represents a 14.10% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 6,906 shares of company stock worth $1,265,855 in the last 90 days. Company insiders own 0.40% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the company. Royal Bank Of Canada increased their price objective on Becton, Dickinson and Company from $180.00 to $190.00 and gave the company a "sector perform" rating in a report on Thursday, August 13th. Evercore set a $180.00 price target on shares of Becton, Dickinson and Company in a report on Monday, July 6th. TD Cowen upped their price objective on shares of Becton, Dickinson and Company from $163.00 to $182.00 and gave the stock a "hold" rating in a research note on Wednesday, August 5th. Jefferies Financial Group reiterated a "buy" rating and set a $210.00 target price on shares of Becton, Dickinson and Company in a research report on Thursday, August 6th. Finally, Barclays initiated coverage on Becton, Dickinson and Company in a research note on Wednesday, October 7th. They set an "underweight" rating and a $165.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Becton, Dickinson and Company has a consensus rating of "Moderate Buy" and an average price target of $185.07.

About Becton, Dickinson and Company

Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops, manufactures and sells a broad range of products used by healthcare providers, clinical laboratories, pharmaceutical companies and patients. Its offerings support medication delivery, diagnostics, infection prevention, surgical care and other clinical procedures.

BD's products include needles, syringes, injection devices, intravenous administration systems, medication-management technologies, specimen-collection products, diagnostic systems and laboratory instruments.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.